Blood Transfusion Guidelines for Adult Patients
I cannot provide 2026 NICE blood transfusion guidelines as they do not exist in the evidence provided—the most recent guidelines available are from 2024-2025.
Core Hemoglobin Threshold Recommendations
For most hospitalized adult patients who are hemodynamically stable, transfuse red blood cells when hemoglobin falls below 7 g/dL 1, 2. This restrictive strategy is supported by high-quality evidence showing no increase in mortality, myocardial infarction, stroke, or other adverse outcomes compared to liberal strategies (transfusing at 9-10 g/dL), while significantly reducing blood product exposure 3, 1.
Clinical Context-Specific Thresholds
The 7 g/dL threshold applies broadly, but specific populations require modified approaches:
Cardiac Surgery Patients:
- Transfuse at hemoglobin <7.5 g/dL 1, 2
- Strong recommendation based on moderate-quality evidence from multiple RCTs
Orthopedic Surgery:
Preexisting Cardiovascular Disease (Stable):
Acute Coronary Syndrome:
- Critical exception: Recent evidence from the MINT trial (2024) favors a liberal strategy with threshold of 10 g/dL 6
- This contradicts older restrictive recommendations
- The REALITY trial showed conflicting results, but MINT was larger and higher quality
- Do not use restrictive thresholds in active ACS—this may worsen outcomes 7
Acute Myocardial Infarction with Anemia:
- Consider transfusion if hemoglobin <8 g/dL on admission 8
- Level 3 recommendation (expert opinion-based)
Traumatic Brain Injury:
- Use liberal strategy: transfuse at hemoglobin <9-10 g/dL 6
- The HEMOTION and TRAIN trials demonstrated better neurological outcomes at 6 months with liberal transfusion
- Restrictive strategies (7 g/dL) associated with worse motor function and quality of life 2, 9
Sepsis and Septic Shock:
- Transfuse at hemoglobin <7 g/dL once tissue hypoperfusion is resolved 3
- Strong recommendation with high-quality evidence
- Individualize during active resuscitation phase
Gastrointestinal Bleeding:
- Restrictive strategy (7 g/dL) reduces 30-day mortality compared to liberal approach 9
- RR 0.63 (95% CI 0.42-0.95)
Critical Exclusions
These thresholds do not apply to:
- Active hemorrhage with hemodynamic instability 8, 1
- Hemorrhagic shock (transfuse immediately) 8
- Severe hypoxemia
- Ongoing acute hemorrhage
Transfusion Practice Principles
Single-Unit Strategy:
- Transfuse one unit at a time in stable patients without active bleeding 8
- Reassess hemoglobin and clinical status after each unit
- Prevents over-transfusion
Beyond Hemoglobin Triggers:
- Never use hemoglobin alone as the sole trigger 8
- Assess: intravascular volume status, evidence of shock, duration/extent of anemia, cardiopulmonary parameters
- Consider symptoms: tachycardia, hypotension, ECG changes, dyspnea
- Alternative markers (central venous oxygen saturation, lactate) lack sensitivity/specificity 6
Transfusion Timing:
- Start infusion within 30 minutes of removal from storage 6
- Use 170-200 μm filter giving sets
- Standard-issue blood (any age within dating period) is safe—no need for "fresh" blood <10 days 4
Platelet Transfusion Thresholds
Prophylactic platelet transfusion when:
- <10,000/mm³ without bleeding 3
- <20,000/mm³ with significant bleeding risk 3
- ≥50,000/mm³ for active bleeding, surgery, or invasive procedures 3
Common Pitfalls to Avoid
Do not transfuse to "improve oxygen consumption" in stable critically ill patients—RBC transfusion is not an absolute method for this 8
Do not use prophylactic FFP to correct abnormal coagulation tests before low-risk procedures in stable critically ill patients 6—PT/APTT poorly predict bleeding
Avoid liberal strategies in most populations—they increase transfusion-related reactions (Peto OR 0.47 for restrictive vs. liberal) 9 without improving outcomes
Do not apply restrictive thresholds to ACS patients—this may cause ~2% increase in new ACS events 7
Recognize the cardiovascular disease paradox: While stable CVD tolerates 8 g/dL threshold, acute coronary syndromes and traumatic brain injury require higher thresholds based on recent high-quality trials 6, 9
Evidence Quality Assessment
The restrictive transfusion strategy is supported by:
- 61 RCTs with 27,639 adult participants 9
- High-certainty evidence for 30-day mortality equivalence (RR 1.01,95% CI 0.90-1.14) 9
- 42% reduction in transfusion exposure (RR 0.58,95% CI 0.52-0.65) 9
The most recent and authoritative guidelines are the 2023 AABB International Guidelines 1 and 2024 American College of Chest Physicians guidelines 2, which supersede older 2012 AABB 5 and 2009 Critical Care Medicine 8 recommendations. The 2025 Association of Anaesthetists guidelines 6 provide the newest evidence on brain injury and ACS populations, representing a significant shift in practice.